3P - Estimated number of Korean women who could benefit from tamoxifen or raloxifene for breast cancer chemoprevention: data from the Korea National Heal...

Date 07 May 2015
Event IMPAKT 2015
Session Welcome reception and Poster Walk
Topics Anti-Cancer Agents & Biologic Therapy
Breast Cancer
Cancer Aetiology, Epidemiology, Prevention
Presenter Myung-chul Chang
Citation Annals of Oncology (2015) 26 (suppl_3): 1-3. 10.1093/annonc/mdv113
Authors M. Chang, J.W. Min
  • Department Of Surgery, Dankook University Hospital, 330-715 - Cheonan/KR

Abstract

Body

Goals: According to the NSABP-P1 and P2 studies, tamoxifen and raloxifene can protect about 50% of breast cancer. These chemopreventive agents were approved for women with a 5-year breast cancer risk of 1.67% or higher. However, they were associated with adverse events, and not all eligible women have a positive risk-benefit index. So we estimated the numbers of Korean women who could benefit from tamoxifen or raloxifene using the data from the Korea National Health and Nutrition Examination Survey (K-NHANES).

Methods: K-NHANES is a nationwide cross-sectional survey to assess the health and nutritional status of Koreans conducted by the Korea Centers for Disease Control and Prevention. We used data of third K-NHANES conducted in 2005. We collected the risk factors of breast cancer and calculated 5-year breast cancer risk of individuals using Korean breast cancer risk assessment model. We calculated an expected number of breast cancer by each individual's sample weights. The numbers of Korean women who have a 5-year risk of 1.67% or higher and who have a positive risk-benefit index with tamoxifen or raloxifene chemoprevention.

Results: Of the 11821464 women aged 35-79 years, only 447174 women (3.8%) had 5-year risk of 1.67% or higher. Most of them were premenopausal women under the age of 50. 2605457 women (22.0%) would have a positive risk-benefit index for tamoxifen chemoprevention and 184670 women (1.6%) would have a positive risk-benefit index for raloxifene chemoprevention.

Conclusion: A small percentage of Korean women would be eligible for chemoprevention according to criteria of 1.67% because of relatively low risks of breast cancer for Koreans. A substantial percentage would have an estimated net benefit by tamoxifen chemoprevention but rarely by raloxifene chemoprevention.

Disclosure: All authors have declared no conflicts of interest.